Loboda, Andrey

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 3,788

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2,498

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,301

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 2,223

Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell

Immune cells in cancerAngiogenesis and VEGF in Cancer

Cited by 653

Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling

Coppola, D., Nebozhyn, M., Khalil, F., Dai, H., Yeatman, T., Loboda, A., & Mulé, J. J. (2011) · The American Journal of Pathology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 434

An unbiased oncology compound screen to identify novel combination strategies

O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics

PI3K/AKT/mTOR signaling in cancerComputational Drug Discovery Methods

Cited by 407

Transcriptional Architecture of the Primate Neocortex

Bernard, A., Lubbers, L. S., Tanis, K. Q., Luo, R., Podtelezhnikov, A. A., Finney, E. M., McWhorter, M. M. E., Serikawa, K., Lemon, T., Morgan, R., et al. (2012) · Neuron

Neurogenesis and neuroplasticity mechanismsSingle-cell and spatial transcriptomics

Cited by 224

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 207

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination

Fourati, S., Cristescu, R., Loboda, A., Talla, A., Filali, A., Railkar, R., Schaeffer, A. K., Favre, D., Gagnon, D., Peretz, Y., et al. (2016) · Nature Communications

Immune responses and vaccinationsHepatitis B Virus Studies

Cited by 183

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 152

Diurnal variation of the human adipose transcriptome and the link to metabolic disease

Loboda, A., Kraft, W. K., Fine, B., Joseph, J., Nebozhyn, M., Zhang, C., He, Y., Yang, X., Wright, C., Morris, M., et al. (2009) · BMC Medical Genomics

Circadian rhythm and melatoninAdipose Tissue and Metabolism

Cited by 124

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRAS Wild-Type, Metastatic Colorectal Cancer

Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors

Cited by 92

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

Schell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 42

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 22